High seroconversion rate after vaccination with mRNA BNT162b2 vaccine against SARS-CoV-2 among people with HIV - but HIV viremia matters?

Our clinical trial of SARS-COV-2 mRNA vaccine in 90 HIV-infected persons on antiviral treatment demonstrated high seroconversion rate and high levels of spike IgG antibodies after two doses of vaccine. The vaccine was well tolerated and not associated with HIV RNA blips. However, the levels of spike IgG antibodies were lower in HIV patients than in healthy controls, especially among those with HIV RNA more than 50 copies/ml at baseline.

Automated summary

Our clinical trial involving 90 HIV-infected individuals on antiviral treatment demonstrated that the SARS-COV-2 mRNA vaccine resulted in a high seroconversion rate and significant levels of spike IgG antibodies after two doses. The vaccine was well tolerated and did not cause HIV RNA blips. However, HIV patients exhibited lower levels of spike IgG antibodies compared to healthy controls, particularly among those with baseline HIV RNA levels exceeding 50 copies/ml.